R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $799.08
    +4.89 (+0.62%)

    Market Cap: $82.27B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +14.39%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$16.00
    Range$14.53 - $17.68
    21 analysts
    EPS Revisions
    19
    0
    7d
    19
    1
    30d
    EPS Estimate Drift
    90d ago$13.08-18.3%
    60d ago$13.08-18.3%
    30d ago$13.12-18.0%
    7d ago$16.05+0.3%
    Current$16.00
    Revenue Consensus
    $4.5B
    Range$4.3B - $4.8B
    19 analysts
    Period ending Dec 31, 2026
    EPS Consensus$18.45
    Range$8.32 - $24.35
    28 analysts
    Revenue Consensus
    $5.1B
    Range$3.2B - $5.8B
    25 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$18.45---
    Sep 26EST
    		-$16.00---
    Jun 26
    Reported Jul 30
    		$12.53$8.00+56.63%Beat-2.8%
    Mar 26
    Reported Apr 29
    		$9.47$8.90+6.40%Beat+15.2%
    Dec 25
    Reported Jan 30
    		$11.44$10.75+6.42%Beat-5.2%
    Sep 25
    Reported Oct 28
    		$11.83$9.64+22.72%Beat-5.1%
    Jun 25
    Reported Aug 1
    		$12.89$8.44+52.73%Beat+11.5%
    Mar 25
    Reported Apr 29
    		$8.22$8.48-3.07%Miss-13.9%
    Dec 24
    Reported Feb 4
    		$12.07$11.19+7.86%Beat+1.8%
    Sep 24
    Reported Oct 31
    		$12.46$11.70+6.50%Beat+7.5%
    Jun 24
    Reported Aug 1
    		$11.56$10.62+8.85%Beat+12.9%
    Mar 24
    Reported May 2
    		$9.55$10.10-5.45%Miss-5.4%
    Dec 23
    Reported Feb 2
    		$11.86$10.75+10.33%Beat-5.6%
    Sep 23
    Reported Nov 2
    		$11.59$10.78+7.51%Beat+4.0%
    Jun 23
    Reported Aug 3
    		$10.24$9.90+3.43%Beat+4.8%
    Mar 23
    Reported May 4
    		$10.09$9.56+5.54%Beat-12.2%
    Dec 22
    Reported Feb 3
    		$12.56$10.01+25.47%Beat-47.0%
    Sep 22
    Reported Nov 3
    		$11.14$9.48+17.51%Beat-27.5%
    Jun 22
    Reported Aug 3
    		$9.77$8.76+11.53%Beat-62.1%
    Mar 22
    Reported May 4
    		$11.49$9.80+17.24%Beat+16.2%
    Dec 21
    Reported Feb 4
    		$23.72$20.30+16.85%Beat+148.9%
    Sep 21
    Reported Nov 4
    		$15.37$9.94+54.63%Beat+83.9%
    Jun 21
    Reported Aug 5
    		$25.80$17.71+45.68%Beat+260.3%
    Mar 21
    Reported May 6
    		$9.89$8.68+13.94%Beat+49.8%
    Dec 20
    Reported Feb 5
    		$9.53$8.29+14.96%Beat+27.1%
    Sep 20
    Reported Nov 5
    		$8.36$6.99+19.60%Beat+25.3%
    Jun 20
    Reported Aug 5
    		$7.16$5.97+19.93%Beat+18.9%
    Mar 20
    Reported May 5
    		$6.60$6.09+8.37%Beat+48.3%
    Dec 19
    Reported Feb 6
    		$7.50$7.17+4.60%Beat+9.6%
    Sep 19
    Reported Nov 5
    		$6.67$6.40+4.22%Beat+13.6%
    Jun 19
    Reported Aug 6
    		$6.02$5.42+11.07%Beat+10.5%
    Mar 19
    Reported May 7
    		$4.45$5.52-19.38%Miss-4.7%
    Dec 18
    Reported Feb 6
    		$6.84$5.60+22.14%Beat+30.8%
    Sep 18
    Reported Nov 6
    		$5.87$5.06+16.01%Beat+47.1%
    Jun 18
    Reported Aug 2
    		$5.45$4.68+16.45%Beat+30.7%
    Mar 18
    Reported May 3
    		$4.67$4.34+7.60%Beat+59.9%
    Dec 17
    Reported Feb 8
    		$5.23$4.57+14.44%Beat+72.0%
    Sep 17
    Reported Nov 8
    		$3.99$3.82+4.45%Beat+27.5%
    Jun 17
    Reported Aug 3
    		$4.17$3.18+31.13%Beat-
    Mar 17
    Reported May 4
    		$2.92$3.07-4.89%Miss-
    Dec 16
    Reported Feb 9
    		$3.04$3.05-0.33%Miss-
    Sep 16
    Reported Nov 4
    		$3.13$2.70+15.93%Beat-

    Dividends

    Dividend Metrics

    Yield0.46%
    Annual/Share$3.70
    Payout Ratio8.79%
    Frequency4
    Pay MonthsMar, Jun, Aug, Sep, Dec

    Key Metrics

    Valuation
    P/E Ratio17.65EV/EBITDA13.54x
    Price/FCF21.84xFCF Yield4.58%
    Profitability
    Profit Margin27.90%Operating Margin33.10%
    ROE14.00%ROIC12.98%
    Financial Health
    Debt/Equity0.06xInterest Coverage94.25x
    Current Ratio3.34xQuick Ratio2.78x
    Trading Statistics
    Beta0.19Avg Volume709.60K
    52-Week High$847.0052-Week Low$538.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$818.96
    SMA 20$804.23
    SMA 50$719.76
    SMA 200$728.06
    EMA 10$808.84
    EMA 20$793.16
    EMA 50$746.09
    EMA 200$705.24

    MACD

    Line: 25.87Signal: 32.99Hist: -7.12

    ADX

    ADX: 47.6+DI: 29.0-DI: 21.0

    Aroon & PSAR

    Aroon Up76.0
    Aroon DownN/A
    PSAR$838.50

    Bollinger Bands

    Upper Band$848.79
    Lower Band$759.67
    %B Position1108%(Upper)
    Band Width0.44

    RSI (14-Day)

    Neutral
    57.6

    Momentum Oscillators

    Stoch %K29.9
    Stoch %D44.2
    Williams %R-70.6
    ROC (10d)-0.7%
    Momentum-5.92
    CCI (20d)-39.1
    MFI (14d)45.9

    Volatility Measures

    ATR (14d)$19.46(2.4%)
    StdDev (20d)22.28
    Hist Vol23.8%(Moderate)

    Volume Flow

    VWAP$793.65
    OBV-793.4K
    AD Line-56.0M
    CMF (20d)0.006

    Volume Metrics

    Avg Vol (20d)702.9K
    Vol Ratio1.1x
    VWMA (20d)$803.74

    Pivot Points

    R3$826.36
    R2$817.88
    R1$806.03
    Pivot Point$797.55
    S1$785.71
    S2$777.23
    S3$765.38

    Advanced Oscillators

    TSI36.77
    Ultimate Osc46.3
    KST172.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$4.29B$3.61B$3.88B$3.75B$3.68B$3.03B$3.79B$3.72B$3.55B$3.15B$3.43B$3.36B
    Cost of Revenue$576.50M$669.40M$584.60M$521.60M$530.20M$464.30M$565.40M$491.10M$480.20M$433.80M$517.00M$436.40M
    Gross Profit$3.71B$2.94B$3.30B$3.23B$3.15B$2.56B$3.22B$3.23B$3.07B$2.71B$2.92B$2.93B
    Operating Expenses$2.42B$2.29B$2.42B$2.21B$2.07B$1.97B$2.23B$2.05B$2.00B$1.96B$1.94B$1.82B
    R&D$1.76B$1.65B$1.64B$1.56B$1.43B$1.34B$1.43B$1.33B$1.22B$1.26B$1.21B$1.18B
    SG&A$662.10M$647.70M$775.00M$657.80M$634.20M$633.00M$792.20M$714.40M$758.80M$689.00M$737.70M$640.50M
    Operating Income$1.29B$642.90M$879.90M$1.03B$1.08B$591.70M$990.20M$1.18B$1.07B$751.40M$972.90M$1.11B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$11.00M$12.90M$12.20M$19.30M$3.60M$8.70M$10.50M$13.80M$14.80M$16.10M$18.30M$17.80M
    Income Before Tax$1.53B$831.20M$1.04B$1.76B$1.52B$905.00M$958.10M$1.49B$1.63B$700.70M$1.15B$1.11B
    Income Tax Expense$230.90M$104.00M$199.10M$303.30M$127.10M$96.30M$40.40M$152.40M$195.80M$-21,300,000$-12,000,000$103.00M
    Net Income$1.30B$727.20M$844.60M$1.46B$1.39B$808.70M$917.70M$1.34B$1.43B$722.00M$1.16B$1.01B
    EBITDA$1.66B$967.30M$1.20B$1.92B$1.66B$1.04B$1.09B$1.63B$1.76B$830.90M$1.28B$1.23B
    EBIT$1.54B$844.10M$1.06B$1.78B$1.52B$913.70M$968.60M$1.51B$1.64B$716.80M$1.17B$1.13B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789, REGN is ~1% above Vulcan's $778 BFV. Not cheap. Not expensive. The market has priced in the base case, leaving alpha entirely in when you buy not if. Dupixent is a compounding machine: Seven US indications and growing, co-commercialized with Sanofi. This isn't just an eczema drug, it's a type-2 inflammation platform that funds REGN's entire R&D pipeline. Fortress balance sheet, real tail risk: D/E of 0.1, 120x interest coverage, Altman Z of 7.8. Yet the 5-year max drawdown is -59.7%. Quality doesn't prevent drawdowns. The alpha zone: Buy zone $715–$730 (~9% pullback). Strong buy $625. Current price above both. Set alerts. No chasing. The patient investor wins here.

    Unknown Author
    •
    2/27/26
    •
    155
    Biotech
    BioPharma
    Also mentions:
    SNY
    AMGN
    TMDX
    GILD

    Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

    Tonight's earnings confirmed the thesis: Q4 revenue $160.8M (+32%), FY $605.5M (+37%), 5,139 OCS cases (+38%), 2026 guidance $727M–$757M. TMDX has graduated from speculative disruptor to verified logistics monopoly. The 22-aircraft fleet is the moat: NOP bundled revenue converts device sales into recurring per-case logistics contracts at 60% gross margins. Building this fleet is what the market punished in 2023 and what it's reprici ROIC 12.1% now exceeds WACC 10.2% (+190 bps spread). This was negative during fleet buildout. Value creation is now confirmed, not projected. Healthcare Barbell context: (GILD) Part 1 is the income anchor, low beta, undervalued, 4%+ yield. (TMDX is the growth compounder. (REGN) Part 3 is the pipeline optionality. Three positions, three roles, one coherent thes

    Unknown Author
    •
    2/25/26
    •
    127
    healthcare-innovation
    Healthcare Stocks
    Also mentions:
    GILD
    REGN

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined lenacapavir guide for 2026. Arcellx acquisition ($7.8B) adds anito-cel CAR-T for multiple myeloma. FDA decision Dec 23, 2026. Logical Kite extension, but differentiation burden is real. At ~17x forward EPS ($8.45-$8.85 guided), you pay fair value for the base and get oncology pipeline optionality essentially free. 2.1% yield while you wait. Vulcan scores: 93 Overall, 93 Value, 88 Quality, 95 Sentiment. Altman Z 4.6, Piotroski F 7, ROIC 19.6%, 78.7% gross margins. Fortress fundamentals. Part 1 of the Healthcare Barbell series: GILD anchors with defensive cash flows (0.37 beta). Part 2 (TMDX) and Part 3 (REGN) incoming. Invalidation: Biktarvy YoY declines in two consecutive quarters or EPS guides lower.

    Unknown Author
    •
    2/24/26
    •
    119
    Healthcare Stocks
    healthcare-innovation
    Also mentions:
    TMDX
    REGN
    JNJ

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x, and $3.6B cash. This is fortress-grade biotech. Q4 revenue crushed estimates by 11% ($1.51B vs $1.35B). Full year $5.14B, up 21%. Core business ex-Jakafi grew 53% to $1.26B. Replacement revenue already $1.26B and guided to grow 30% in 2026. Management targets $3-4B core ex-Jakafi by 2030, turning the patent cliff into a slope. Post-earnings pullback breached first buy zone. Three tranches: current levels near $100, $96-$99 (channel support), $88-$92 (200-day defense). Blended fair value ~$155 implies ~55% upside. Four product launches on deck late 2026/early 2027: Jakafi XR, Opzelura moderate AD, Monjuvi sBLA, Povorcitinib.

    Unknown Author
    •
    2/11/26
    •
    129
    Biotech
    Healthcare Stocks
    Also mentions:
    NVS
    LLY
    REGN
    GILD

    Government Contracts

    Gov Obligations (TTM)
    -$329.36M
    Gov Obligations / Revenue
    -2.1%
    Obligations YoY
    N/A
    Active Awards
    3
    New Awards (TTM)
    0
    Avg Remaining Term
    13.8 mo

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    CytomX Therapeutics to Present at Upcoming September Investor Conferences

    CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced that its management will participate in three investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. The company, a leader in masked, conditionally activated biologics, will present during fireside chats at each event, with live webcasts available on their website. Management will also be available for one-on-one meetings with registered investors.

    The Manila Times•9/1/26•
    Neutral

    IQVIA Holdings Inc. (IQV) Peer Comparison – Compare with Others

    This article provides a detailed peer comparison for IQVIA Holdings Inc. (IQV) against other biotechnology companies like Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna, and Revolution Medicines. It presents key financial metrics including market cap, revenue, net profit, profitability ratios, growth ratios, valuation ratios, solvency ratios, and operating efficiency ratios, allowing investors to analyze IQV's performance relative to its competitors. The data covers income statements, liabilities, assets, cashflow, and various financial ratios for each company.

    Value Research•8/30/26•
    Neutral

    FDA grants fast track status to CytomX’s colorectal cancer drug

    The FDA has granted Fast Track Designation to CytomX Therapeutics' drug, Varseta-M, for treating relapsed/refractory metastatic colorectal cancer. This designation acknowledges the drug's potential to address a significant unmet medical need and will expedite its development and review process. CytomX plans to initiate a registrational study for Varseta-M in the first half of 2027.

    Investing.com•8/27/26•
    Neutral

    CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

    CytomX Therapeutics announced that the FDA has granted Fast Track Designation to Varsetatug masetecan (Varseta-M) for the treatment of relapsed/refractory metastatic colorectal cancer. This designation follows encouraging Phase 1 data and aims to expedite the development and review of Varseta-M, which is designed to address a high unmet medical need in this patient population. CytomX plans to initiate a potential monotherapy registrational study for Varseta-M in the first half of 2027.

    Yahoo Finance•8/27/26•
    Somewhat-Bullish

    B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential

    B.Riley has initiated coverage on Cardiol Therapeutics Inc. (NASDAQ:CRDL) with a Buy rating and a price target of $11.00, citing the significant potential of its lead drug candidate, CardiolRx. The drug, an oral maintenance therapy for recurrent pericarditis, is currently in a pivotal Phase 3 trial with top-line data expected in Q1 2027. Cardiol Therapeutics also boasts a strong balance sheet, providing financial stability for its clinical programs.

    Investing.com•8/26/26•
    Neutral

    Frequently Asked Questions About REGN

    What is REGN's current dividend yield?
    Regeneron Pharmaceuticals Inc (REGN) has a current dividend yield of 0.46%.
    Does REGN pay dividends?
    Yes, Regeneron Pharmaceuticals Inc pays dividends with a current yield of 0.46%.
    What is REGN's P/E ratio?
    Regeneron Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 17.65.
    What is REGN's market cap?
    Regeneron Pharmaceuticals Inc (REGN) has a market capitalization of $82.27B with a current stock price of $799.08.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In